This is your wake up call.
Most of our industry is still treating CMS payment changes like background noise. Big mistake.
The finalization of CJR-X isn’t another incremental reimbursement tweak. It’s a forced rewrite of the hospital purchasing playbook that will decide which device companies stay relevant after January 1, 2028. Hospitals will no longer evaluate our implants, robotics, or enabling tech purely on clinical features or unit price.
They will evaluate us on whether we help them survive a 90-day financial and quality accountability model.
The companies that understand this distinction—and act on it—will own the next decade of joint reconstruction. The ones that don’t will watch their trays gather dust. Here’s exactly what that means for every orthopedic manufacturer still selling hardware in America.
Let's dive into the details
Mandatory for most U.S. acute-care hospitals starting January 1, 2028, CJR-X holds providers financially accountable for Medicare spend and quality across a 90-day episode for hip, knee, and ankle replacements. Covering the procedure, post-acute care, physical therapy, and readmissions, CMS projects roughly $725 million in net savings over fiv...
